14-day Premium Trial Subscription Try For FreeTry Free
$25.38
+0.0200 (+0.0789%)
At Close: May 02, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $14.00 $25.47 Thursday, 2nd May 2024 DCPH stock ended at $25.38. This is 0.0789% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 0.493% from a day low at $25.35 to a day high of $25.47.
90 days $13.86 $25.47
52 weeks $9.90 $25.47

Historical Deciphera Pharmaceuticals Inc prices

Date Open High Low Close Volume
Nov 01, 2023 $12.00 $12.37 $11.73 $11.86 1 122 378
Oct 31, 2023 $12.35 $12.35 $11.27 $11.99 1 668 817
Oct 30, 2023 $11.41 $12.70 $11.07 $11.93 3 530 825
Oct 27, 2023 $10.23 $10.31 $10.04 $10.15 542 849
Oct 26, 2023 $10.25 $10.52 $10.13 $10.18 729 793
Oct 25, 2023 $10.28 $10.41 $9.90 $10.11 576 084
Oct 24, 2023 $10.43 $10.59 $10.22 $10.39 358 665
Oct 23, 2023 $10.12 $10.30 $9.99 $10.21 346 062
Oct 20, 2023 $10.63 $10.63 $10.18 $10.21 487 856
Oct 19, 2023 $10.87 $10.87 $10.43 $10.56 440 305
Oct 18, 2023 $10.42 $10.87 $10.24 $10.82 417 938
Oct 17, 2023 $10.94 $11.17 $10.51 $10.57 648 395
Oct 16, 2023 $10.94 $10.99 $10.61 $10.83 339 753
Oct 13, 2023 $10.83 $11.06 $10.55 $10.95 405 536
Oct 12, 2023 $11.04 $11.22 $10.54 $10.78 577 798
Oct 11, 2023 $11.51 $11.52 $10.76 $10.90 486 456
Oct 10, 2023 $10.50 $11.53 $10.49 $11.45 2 078 444
Oct 09, 2023 $12.08 $12.11 $10.98 $11.02 1 438 771
Oct 06, 2023 $12.38 $12.49 $11.89 $12.14 1 058 974
Oct 05, 2023 $12.30 $13.13 $12.30 $12.48 750 156
Oct 04, 2023 $12.65 $12.70 $12.44 $12.46 404 471
Oct 03, 2023 $12.57 $12.74 $12.49 $12.68 256 331
Oct 02, 2023 $12.68 $13.17 $12.59 $12.62 745 520
Sep 29, 2023 $12.79 $12.84 $12.55 $12.72 268 490
Sep 28, 2023 $12.67 $12.77 $12.33 $12.74 275 668
Click to get the best stock tips daily for free!

About Deciphera Pharmaceuticals Inc

Deciphera Pharmaceuticals Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. Th... DCPH Profile

Golden Star

Ticker Date Change Price
HRB Apr 29 1.00% $47.23
LYG Apr 29 0.391% $2.56
ORA Apr 29 1.95% $64.48
ETSY Apr 26 3.43% $67.43
DHT Apr 24 0.98% $11.28
LPLA Apr 19 1.10% $262.59
MLI Apr 19 7.29% $52.28
PFLT Apr 18 1.33% $11.25
DOOR Apr 18 0.94% $131.39
OCSL Apr 17 0.360% $19.43
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT